Literature DB >> 36116082

Combined analysis of clinical features, human chorionic gonadotropin (hCG) value, and hCG ratios for early prediction of postmolar gestational trophoblastic neoplasia.

Chanya Rakprasit1, Irene Ruengkhachorn2, Suwanit Therasakvichya2, Perapong Inthasorn2, Vuthinun Achariyapota2, Sompop Kuljarasnont2, Khemanat Khemworapong2, Nida Jareemit3.   

Abstract

PURPOSE: To investigate factors predicting postmolar gestational trophoblastic neoplasia (GTN) by combined analysis of clinical features, human chorionic gonadotropin (hCG) value, and hCG ratios.
METHODS: This retrospective study enrolled patients with histopathologically proven molar pregnancy. Patients lost to follow-up before remission or developing postmolar GTN were excluded. Demographic and clinical characteristics and hCG data obtained before and after molar evacuation were collected. Area under the receiver operating characteristic curve (AUC) analysis was used to identify the hCG and hCG ratio cutoff values that predict postmolar GTN. Multivariate analysis was employed to identify independent predictors of GTN.
RESULTS: There were 113 complete moles, 11 partial moles, and 52 unspecified moles included in the final analysis. Of the 176 cases, 90 achieved remission and 86 developed post-molar GTN. The incidence of postmolar GTN was 48.9%, with a median time to GTN development of 5 weeks. Univariate analysis showed age, molar evacuation performed elsewhere, pre-evacuation hCG, hCG at 2nd week post-evacuation, and ratio of hCG at 2nd week post-evacuation to post-evacuation hCG significantly predict GTN. Multivariate analysis revealed an hCG value ≥ 1400 IU/L at 2nd week post-evacuation (AUC: 0.92, aOR: 6.51, 95% CI 1.28-33.16; p = 0.024) and a ratio of hCG at 2nd week post-evacuation to post-evacuation hCG of ≥ 0.02 (AUC: 0.88, aOR: 12.27, 95% CI 2.15-70.13; p = 0.005) to independently predict GTN.
CONCLUSIONS: An hCG value ≥ 1400 IU/L at 2nd week post-evacuation and a ratio of hCG at 2nd week post-evacuation to post-evacuation hCG of ≥ 0.02 independently and reliably predict postmolar GTN.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Gestational trophoblastic disease; High risk; Hydatidiform mole; Molar pregnancy; Predict

Year:  2022        PMID: 36116082     DOI: 10.1007/s00404-022-06785-w

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.493


  7 in total

1.  Management of high-risk hydatidiform mole and persistent gestational trophoblastic neoplasia: the Korean experience.

Authors:  Seung Jo Kim; Young Jeong Na; Sang Geun Jung; Chan Joo Kim; Seog Nyeon Bae; Chan Lee
Journal:  J Reprod Med       Date:  2007-09       Impact factor: 0.142

2.  Gestational trophoblastic disease. Subsequent pregnancy outcome, including repeat molar pregnancy.

Authors:  R S Berkowitz; S S Im; M R Bernstein; D P Goldstein
Journal:  J Reprod Med       Date:  1998-01       Impact factor: 0.142

3.  Predictors of persistent disease in women with complete hydatidiform mole.

Authors:  A Ayhan; Z S Tuncer; H Halilzade; T Küçükali
Journal:  J Reprod Med       Date:  1996-08       Impact factor: 0.142

4.  Complete hydatidiform mole in women aged 40 to 49 years.

Authors:  Kevin M Elias; Melina Shoni; Marilyn Bernstein; Donald P Goldstein; Ross S Berkowitz
Journal:  J Reprod Med       Date:  2012 May-Jun       Impact factor: 0.142

Review 5.  Advances in the epidemiology of gestational trophoblastic disease.

Authors:  J R Palmer
Journal:  J Reprod Med       Date:  1994-03       Impact factor: 0.142

Review 6.  Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia.

Authors:  Qiuyi Wang; Jing Fu; Lina Hu; Fang Fang; Lingxia Xie; Hengxi Chen; Fan He; Taixiang Wu; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2017-09-11

7.  Timing of Referral to the New England Trophoblastic Disease Center: Does Referral with Molar Pregnancy Versus Postmolar Gestational Trophoblastic Neoplasia Affect Outcomes?

Authors:  Elisabeth J Diver; Neil S Horowitz; Donald P Goldstein; Marilyn Bernstein; Ross S Berkowitz; Whitfield B Growdon
Journal:  J Reprod Med       Date:  2016 May-Jun       Impact factor: 0.142

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.